SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017)
-
M. Martínez-Garcia [9] ; J. Álvarez-Linera [1] ; C. Carrato [2] ; L. Ley [3] ; R. Luque [4] ; X. Maldonado [5] ; M. Martínez-Aguillo [6] ; L. M. Navarro [7] ; M. A. Vaz-Salgado [3] ; M. Gil-Gil [8]
-
[1] Hospital Ruber Internacional
Hospital Ruber Internacional
Madrid, España
-
[2] Hospital Universitari Germans Trias i Pujol
Hospital Universitari Germans Trias i Pujol
Barcelona, España
-
[3] Hospital Ramón y Cajal
Hospital Ramón y Cajal
Madrid, España
-
[4] Hospital Universitario Virgen de las Nieves
Hospital Universitario Virgen de las Nieves
Granada, España
-
[5] Hospital Vall d'Hebron
Hospital Vall d'Hebron
Barcelona, España
-
[6] Gobierno de Navarra
Gobierno de Navarra
Pamplona, España
-
[7] Hospital Universitario de Salamanca
Hospital Universitario de Salamanca
Salamanca, España
-
[8] Institute Catalá Oncología
Institute Catalá Oncología
Barcelona, España
-
[9] Hospital del Mar-Parc de Salut Mar, España
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 20, Nº. 1 (January 2018), 2018, págs. 22-28
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Glioblastoma (GB) is the most common brain malignancy and accounts for over 50% of all high-grade gliomas. Radiotherapy (RT) with concomitant and adjuvant temozolomide (TMZ) chemotherapy is the current standard of care for patients with newly diagnosed GB up to age 70. Recently, a new standard of care has been adopted for elderly patients (≥ 65 years) based on short course of RT and TMZ. Several clinically relevant molecular markers that assist in diagnosis and prognosis have recently been identified. The treatment for recurrent GB is not well defined, and decision-making is usually based on prior strategies as well as several clinical and radiological factors. The presence of neurologic deficits and seizures can significantly impact quality of life.
